Who
Judy D. Olian
Director
Company insider
Files Form 4 as: Director, Ares Management; Director, United Therapeutics; Director, Mattel.
In numbers
- Trades disclosed
- 126
- Buys
- 2
- Sells
- 20
- Bought
- $149K
- Sold
- $14.4M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 1 May 2014
- Last trade
- 30 Jul 2026
- Last filed
- 3 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jul 2026filed 3 Aug 2026 | ARES Ares ManagementCapital Markets & Asset Management | SEC FORM 4 Code A | —1,728 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | ARES Ares ManagementCapital Markets & Asset Management | SEC FORM 4 Code A | —1,728 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —760 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —760 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,310 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,310 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,310 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,310 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | MAT Matteloption or derivative · Leisure Products & Vehicles | SEC FORM 4 Code A | —11,753 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | MAT Matteloption or derivative · Leisure Products & Vehicles | SEC FORM 4 Code A | —11,753 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MAT MattelLeisure Products & Vehicles | SEC FORM 4 Code M | —8,594 | filing |
| 15 May 2026filed 19 May 2026 | MAT Matteloption or derivative · Leisure Products & Vehicles | SEC FORM 4 Code M | —8,594 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MAT Matteloption or derivative · Leisure Products & Vehicles | SEC FORM 4 Code M | —8,594 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MAT MattelLeisure Products & Vehicles | SEC FORM 4 Code M | —8,594 | filing |
| 23 Mar 2026filed 24 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $106K200 at $530.00 | filing |
| 23 Mar 2026filed 24 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $106K200 at $530.00 | filing |
| 16 Mar 2026filed 16 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K200 at $535.44 | filing |
| 16 Mar 2026filed 16 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K200 at $535.44 | filing |
| 6 Mar 2026filed 9 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $102K200 at $510.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $102K200 at $510.00 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)UTHR · dailypolitical.com · 18 Oct 2026United Therapeutics (NASDAQ: UTHR) general counsel sells 8,300 shares under planUTHR · themarketsdaily.com · 17 Oct 2026Ares Management (NYSE:ARES) Price Target Cut to $159.00 by Analysts at TD CowenARES · dailypolitical.com · 13 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)UTHR · themarketsdaily.com · 12 Oct 2026Critical Survey: Galaxy Digital (NASDAQ:GLXY) and Ares Management (NYSE:ARES)ARES · themarketsdaily.com · 7 Oct 2026Comparing Ares Management (NYSE:ARES) & Coinbase Global (NASDAQ:COIN)ARES · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Judy D. Olian; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.